Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV-CTLs for CMV Prophylaxis in Haploidentical HSCT
NCT04056533Phase 2Recruiting
- Sponsor
- IDIVAL
- Start
- Mar 2022
- Primary completion
- Mar 2026
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
A Phase 2 trial of cytomegalovirus-specific cytotoxic T lymphocytes in cytomegalovirus infection (CMV), sponsored by IDIVAL. Started Mar 2022; status: recruiting.
02
Drugs
cytomegalovirus-specific cytotoxic T lymphocytes
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT04056533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04056533.